Iressa’s revenue trends
In 3Q17, AstraZeneca’s (AZN) Iressa generated revenues of $137.0 million, which reflected ~10.0% growth on a year-over-year (or YoY) basis. Iressa’s quarter-over-quarter revenues remained flat in 3Q17.
Iressa reported 9M17 revenues of $398.0 million, which represents ~1.0% growth on a YoY basis. Iressa’s 9M17 sales witnessed 7.0% growth in emerging markets with product sales in China witnessing 17.0% growth.
Iressa (gefitinib) is used as a first-line treatment for individuals with metastatic non-small cell lung cancer (or NSCLC). These individuals’ tumors showed EGFR (epidermal growth factor receptor) exon 19 deletion or exon 21 substitution.
Iressa’s peers in the NSCLC drugs market include Roche’s (RHHBY) Tarceva and Boehringer Ingelheim’s Gilotrif.
Zoladex’s revenue trends
In 3Q17, Zoladex generated revenues of $185.0 million, which reflected an ~7.0% decline on a YoY basis and 4% growth quarter-over-quarter. Zoladex reported 9M17 revenues of $548.0 million, which is an ~6.0% decline on a YoY basis.
Zoladex (goserelin) and flutamide combination therapy are used for the treatment of locally confined prostate cancer. Zoladex is also indicated for the palliative treatment of advanced carcinoma of the prostate.
Casodex’s revenue trends
In 3Q17, Casodex generated revenues of $51.0 million which is an ~18.0% decline on a YoY basis and a 6.0% decline quarter-over-quarter. Casodex reported 9M17 revenues of $161.0 million, which represents ~14% growth on a YoY basis.
Casodex (bicalutamide) is used in the treatment of prostate cancer. Some important drugs in the prostate cancer drugs market include Sanofi’s (SNY) Jevtana, AbbVie’s (ABBV) Lupron, and Astellas Pharma’s Xtandi.
Arimidex’s revenue trends
In 3Q17, Arimidex generated revenues of $54.0 million, which reflected an ~4.0% decline on a YoY basis. Arimidex reported 9M17 revenues of $160.0 million which is an ~9% decline on a YoY basis.
Arimidex (anastrozole) is used in the treatment of postmenopausal women with hormone receptor-positive early breast cancer and metastatic breast cancer.
AstraZeneca comprises ~0.14% of the Vanguard Total International Stock ETF’s (VXUS) portfolio holdings.